Tag Archives: MK

Mortal Kombat: Legacy – Get Ready for Fatalities

Cast members Casper Van Dien (Johnny Cage), Brian Tee (Liu Kang), Ian Anthony Dale (Scorpion), Samantha Jo (Kitana), and MK creator Ed Boon appeared on the Mortal Kombat: Legacy panel at San Diego Comic-Con Thursday, alongside director Kevin Tancharoen, producer Lance Sloane and Machinima Exec VP of Network Programming Aaron DeBevoise, to discuss the upcoming second season of the successful web series.

“Fatalities” was the word of the day, as just about everyone on the panel hammered the point home that Season 2 would be more amped up, brutal and include – yes – fatalities. All the actors were enthusiastic about having more rehearsal time for the fight scenes this time around, which they insisted would be faster, harder and better than the first season. Fans can also expect one linear storyline this time out, where they’ll see the characters fighting in the tournament.

Continue reading…

…read more

Source: FULL ARTICLE at IGN Video Games

Kevin Smith Gets His Game On With Jason Mewes Playing Injustice: Gods Among Us

By John Gaudiosi, Contributor

NetherRealm Studios’ new fighting game, Injustice: Gods Among Us, is already getting rave reviews from gaming sites. It’s the second time the Warner Bros. Interactive Entertainment-owned studio, NetherRealm, has worked with some of the most famous DC Comics super heroes like Superman, Batman, Wonder Woman, Arrow and The Flash in a video game. MK vs DC Universe was a hit years ago, but this new game rids the Mortal Kombat characters and delves into the Injustice comic book mythology that allows some of the most iconic super heroes to turn on each other in combat. It’s also worth noting that both of these games run on Epic Games’ Unreal Engine 3 technology.

From: http://www.forbes.com/sites/johngaudiosi/2013/04/20/kevin-smith-gets-his-game-on-with-jason-mewes-playing-injustice-gods-among-us/

Can Merck Field a Psoriasis Blockbuster?

By Maxx Chatsko, The Motley Fool

Filed under:

Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade. How massive? The market was sized up at an estimated $72.2 billion in 2010, according to BCC Research — and growth isn’t slowing any time soon. That’s good news for patients, too. The pharmaceutical industry’s fascination with an improved understanding of biologics has led to dozens of drugs that treat the underlying causes of diseases, rather than small molecules of years past that only treated symptoms.  

Few companies haven’t joined the rush to develop biologics and novel small molecule classes to treat immune diseases. While some companies got a big head start over the field, next-generation therapies are being developed in pipelines across the industry. Merck is one company looking to capitalize on the trend and will shortly begin phase 3 trials on its leading psoriasis biologic therapy candidate. Going by the catchy pipeline name of MK-3222, the drug has huge potential if it ever receives approval from the Food and Drug Administration, or FDA.

About that competition I mentioned…
Older therapies aren’t exactly losing their grasp on the markets they took by storm just yet. A quick look at 2012 sales data from the first three biologics approved that work by inhibiting the TNF-alpha protein — integral to immune system communication — shows exactly that.

Company

Drug

2012 Sales

Johnson & Johnson

Remicade

$6,139 million

Amgen

Enbrel

$4,236 million

AbbVie

Humira

$9,265 million

Source: Company 2012 earnings.       

Aside from the big three, there are newer therapies on the market and in development that target TNF-alpha indirectly by inhibiting the proteins further upstream in the cellular communication chain. For instance, Johnson & Johnson’s Stelara binds to interleukin 23 and interleukin 12, which regulate TNF-alpha production. The therapy has been approved for psoriasis and is in late stage trials for Crohn’s disease and ankylosing spondylitis.

The biggest advantage for new therapies may lie in dosing schedules. Consider that during a 12-week study comparing Stelara to Enbrel, the TNF-alpha inhibitor was administered twice a week for the length of the study, while the drug candidate was administered just twice over the same period. Stelara still managed to beat Enbrel in high-dose groups with 71% and 49% of patients responding, respectively.   

Is it too late for Merck?
The dosing regimen of Stelara raises the bar significantly for all therapies. However, Merck’s MK-3222 has essentially the same requirements; administered twice in the first four weeks of treatment and then once every 12 weeks thereafter. The two therapies work in slightly different ways, too, with MK-3222 targeting a different region of interleukin 23 while sparing interleukin 12. In theory, that could make the drug less destructive to a patient’s immune system, which is the biggest drawback to many immune disease therapies.  

Two other biologics mirroring this mechanism of action are in development across …read more

Source: FULL ARTICLE at DailyFinance

Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vanip

By Business Wirevia The Motley Fool

Filed under:

Merck to Present New Data on VICTRELIS ® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver Congress TM / 2013 EASL Annual Meeting

WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)– Merck (NYS: MRK) , known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck’s investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013.

Key Presentations About VICTRELIS 200 mg Capsules

  • Safety And Efficacy Of Boceprevir/Peginterferon/Ribavirin (Boc/P/R) Combination Therapy For Chronic HCV G1 Patients With Compensated Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M. Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI Convention Centre.
  • Virologic Response Rates Are Similar In Previously Untreated And Previously Treated And Relapsed Patients Receiving Boceprevir Triple Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791. Friday, April 26, 12:30-14:00. RAI Convention Centre.

Key Investigational Compound Presentations

  • High Sustained Viral Response at 12- and 24-week follow-up of MK-5172 with Pegylated Interferon alfa-2b and Ribavirin (PR) in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients. Manns, M. et al. Oral Presentation: Friday, April 26, 16:00-18:00, RAI Convention Centre.
  • MK-5172 In Combination With Peg-Interferon And Ribavirin Elicits Limited Resistance While Demonstrating Robust Efficacy In Treatment Naïve Genotype 1 Chronic HCV-Infected Patients. Howe, A. et al. Poster 1197. Saturday, April 27, 12:30-13:30. RAI Convention Centre.
  • Sustained Viral Response And Safety Of MK-7009 In Cirrhotic Treatment-Experienced Patients With Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon And Ribavirin Treatment. Rodriguez-Torres, M. et al. Oral Presentation. Saturday, April 27, 8:30-10:30. RAI Convention Centre.

“We are pleased to present new data on VICTRELIS that will help inform health care professionals as they consider the use of VICTRELIS in appropriate patients,” said Eliav Barr, M.D., vice president, Infectious Diseases, Project Leadership and Management, Merck Research Laboratories. …read more

Source: FULL ARTICLE at DailyFinance

Pentagon Awards German Firm a $343.6 Million Missile Contract

By Rich Smith, The Motley Fool

Filed under:

In a concrete demonstration of bilateral military cooperation, the U.S. Department of Defense announced Thursday that it has awarded a firm-fixed-price contract worth $343.6 million to German defense firm RAMSYS GmbH. The contract calls for RAMSYS to supply “445 Block 2 MK-44 Mod 4 Rolling Airframe Missile (RAM) Guided Missile Round Pack (GMRP) All-Up-Rounds (AURs).”

That’s quite a mouthful, and probably requires some explaining. RAMSYS, aka RAM System GmbH, is a Raytheon partner and a joint venture among three European defense firms: privately held Diehl Stiftung owns 25% of RAMSYS, its subsidiary Diehl BGT Defence owns a further 25%, and MBDA Holdings — itself owned by BAE Systems , EADS , and Finmeccanica — owns the remaining 50% of RAMSYS.

RAMSYS‘s near-sole raison d’etre is to build Rolling Airframe Missiles — the “RAM” in RAMSYS — for Europe‘s militaries.

As for the RAM itself, this is an anti-aircraft and anti-cruise missile defense system used on multiple ship platforms in Europe, and was co-developed, and is co-produced, by the U.S. and German governments. The RAM got its name because the surface-to-air missiles that it fires tend to spin or “roll” while in flight. The system is currently in service on about 78 U.S. Navy warships, and aboard 30 German vessels, and the Navies of South Korea, Egypt, Greece, Japan, Turkey, and the UAE are all considering, or have already begun adopting, the RAM, as well.

The Pentagon contract awarded Thursday is expected to be completed by January 2019, and will be 100% paid for by the German government.

 
 

The article Pentagon Awards German Firm a $343.6 Million Missile Contract originally appeared on Fool.com.

Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool owns shares of Raytheon Company. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r …read more
Source: FULL ARTICLE at DailyFinance

Northrop Wins $34 Million in New Pentagon Contracts

By Rich Smith, The Motley Fool

Filed under:

On Friday, the Department of Defense awarded Northrop Grumman two contracts worth a combined $34 million.

The first contract modifies an existing contract by awarding Northrop $28.6 million to provide engineering and production planning services for Mission Packages that will be used aboard Navy Littoral Combat Ships, or LCSes. “Mission Packages” are a relatively new concept for the Navy and consist of standardized sets of equipment, sensors, and crew (Mission Modules) that can be loaded aboard an LCS to transform it into a ship designed for a specific mission.

Think of the LCS as the base plate in a Lego set. Depending on what kind of mission you might need to perform, different sizes and colors of Legos (Mission Modules) could be added to the base plate to build a complete Mission Package. For example, an LCS equipped for a surface warfare mission might be equipped with MK 46 and MK 44 cannons and associated rounds, surface-to-surface missiles, and an MH-60R Seahawk helicopter. LCSes destined for other missions might receive equipment better suited for minesweeping, for anti-submarine warfare, for anti-piracy, and so on.

Northrop’s role in the instant contract is to assist in picking out the right “Legos,” and evaluating how they work through a dynamic process of “continuous evaluation.”

The company’s role in the second contract is more straightforward. For $5.4 million, Northrop will support U.S. Army efforts to develop digitized communications among units on the battlefield, a project referred to as the “Lower Tactical Internet.” Northrop will continue its work here through Sept. 12.

The article Northrop Wins $34 Million in New Pentagon Contracts originally appeared on Fool.com.

Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool owns shares of Northrop Grumman. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
…read more
Source: FULL ARTICLE at DailyFinance

Merck's Companion in the Fight Against Alzheimer's

By Max Macaluso, Ph.D., The Motley Fool

Filed under:

A cure for Alzheimer’s disease is one of the most sought-after prizes in the pharmaceutical industry today. The tragic degenerative effects of this illness are widely known, but drugmakers have been unable to find medicines that can effectively slow its progression. The development of a drug shared by Pfizer, Johnson & Johnson, and Elan was stopped last summer, and Eli Lilly‘s phase 3 compound solanezumab displayed mixed results after the data was analyzed last autumn. Pharma titan Merck  is also in the race to find an effective treatment with its experimental Alzheimer’s drug, called MK-8931, and the company is currently enrolling patients in its phase 2/3 study.

Today, in an effort to enroll the appropriate subgroup of patients in its study, Merck announced that it has an agreement in place with Luminex for a companion diagnostic that can help diagnose Alzheimer’s disease. Health-care Max Macaluso analyst discusses the importance of this deal in the following video.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company’s moving parts, its major market opportunities, and reasons to both buy and sell. To find out more, click here to claim your copy today.

var FoolAnalyticsData = FoolAnalyticsData || []; FoolAnalyticsData.push({ eventType: “TickerReportPitch”, contentByline: “Max Macaluso, Ph.D.”, contentId: “cms.23696”, contentTickers: “NYSE:MRK, NASDAQ:LMNX”, contentTitle: “Merck’s Companion in the Fight Against Alzheimer’s”, …read more
Source: FULL ARTICLE at DailyFinance

Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigati

By Business Wirevia The Motley Fool

Filed under:

Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease

Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease

WHITEHOUSE STATION, N.J. & AUSTIN, Texas–(BUSINESS WIRE)– Merck (NYS: MRK) , known as MSD outside the United States and Canada, and Luminex Corporation (NAS: LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck’s clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck’s lead investigational candidate for Alzheimer’s disease (AD). Financial terms were not disclosed.

“Evaluation of biomarkers that may provide an indicator of disease onset and enable earlier diagnosis is an important goal toward facilitating early intervention and potentially improving the treatment of Alzheimer’s disease,” said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience and Ophthalmology at Merck Research Laboratories. “We look forward to working with Luminex to advance our ongoing clinical development program for MK-8931.”

Luminex will be responsible for development, regulatory submission and commercialization of the candidate companion diagnostic device, which will employ Luminex’s xMAP® Technology to measure concentrations of two candidate biomarkers (Aβ42 and t-tau) in cerebrospinal fluid (CSF) samples from patients with mild cognitive impairment (MCI). The candidate device will be evaluated as a means to identify subjects with MCI who have a higher risk of developing AD to support patient selection for Merck’s therapeutic BACE inhibitor clinical program.

“This collaboration has the potential to deliver a novel companion diagnostic to identify patients at increased risk of developing Alzheimer’s disease,” added Patrick J. Balthrop, president and CEO of Luminex. “We are pleased to leverage our technologies and development capabilities and look forward to expanding our activity into the companion diagnostic segment of personalized medicine.”

The accumulation of beta amyloid in the brain is a key pathological characteristic related to AD. Recent clinical evidence supports the hypothesis that the measurement of the investigational biomarkers Aβ42 and t-tau in CSF may be useful in identifying patients at greater risk of developing AD. Currently, AD is diagnosed by clinical examination (i.e., medical history; physical, neurological, psychiatric and neuropsychological exams; and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be …read more
Source: FULL ARTICLE at DailyFinance

Mortal Kombat: Legacy Season 2 Trailer

The trailer has debuted for Mortal Kombat: Legacy II, the second season of the MK webseries. Get a look at what’s to come, as this season takes the characters into the actual tournament.

Kevin Tancharoen returns to co-write and direct a cast that includes Harry Shum, Jr. (Glee) as Kuai Liang, Casper Van Dien (Starship Troopers) as Johnny Cage, Brian Tee (The Wolverine) as Liu Kang, Mark Dacascos (Hawaii Five-0) as Kung Lao, Ian Anthony Dale (Hawaii Five-O) as Scorpion and, reprising his role from the 1995 Mortal Kombat film, Cary Tagawa (Revenge) as Shang Tsung.

Check out the trailer below, which debuted during the Streamy Awards.

Continue reading…

…read more
Source: FULL ARTICLE at IGN Video Games